Watertown, MA – Nocion Therapeutics has announced the appointment of Vineet Agarwal as Chief Business Officer. About Nocion Therapeutics: Nocion Therapeutics is a biopharmaceutical company developing a new class of charged sodium channel blockers to treat chronic cough and other diseases driven by sensory neuron hypersensitivity. Its lead candidate, taplucainium, is a first in class inhaled therapy designed to silence the nerve signaling that drives refractory and unexplained chronic cough at its source. The companys proprietary nocion platform is built to selectively, locally, and durably silence activated nociceptorsoveractive sensory neurons that underlie many chronic conditions. Nocion is leveraging this foundational scientific platform not only for chronic cough, one of the most common yet poorly treated reasons for physician visits in the U.S., but also to develop new medicines for other debilitating chronic conditions where overactive sensory nerves cause lasting harm. The company highlights that its Phase 2b ASPIRE study of taplucainium is fully enrolled, signaling meaningful clinical progress toward addressing a condition for which no new therapies have been approved in more than 60 years.

For more information visit: https://www.nociontx.com/

Nocion Therapeutics
15 Main St PMB 247
Watertown, MA 2472
Phone: 781-819-2877
LinkedIn: https://www.linkedin.com/company/nocion-therapeutics-inc/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved